Company intelligence / Profile preview

Transition Therapeutics Inc.

Toronto, Ontario, Canadatransitionbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Transition Therapeutics was a Toronto-based biopharmaceutical company focused on developing novel small molecule therapies targeting central nervous system disorders such as Alzheimer’s disease and metabolic diseases like type 2 diabetes. Its lead program ELND005 reached late-stage clinical trials for agitation/aggression in Alzheimer’s patients. The company also developed TT401 with Eli Lilly for diabetes/obesity and TT701 targeting androgen deficiency. In mid‑2016, the company was acquired by OPKO Health.

Therapeutic areas: EndocrinologyRare DiseasesNeurologyMen's Health
Modalities: Small moleculesSelective androgen receptor modulators (SARMs)Other novel therapeutics for CNS and metabolic diseases
Industry: Biotech

Partnerships

Eli Lilly & Co. — collaboration/licensing agreement on TT401/metabolic compounds development/commercializationElan Pharmaceuticals — partnership on ELND005 development for Alzheimer’s disease

Beyond the preview

Go deeper on Transition Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transition Therapeutics Inc..

Explore the full profile